I remember that until recently, miracle medicines that could heal and restore a person almost instantly belonged exclusively to science fiction, and as a fan of the genre, the one thing I never expected was to live long enough to see it happen —or at least that’s what seems to be unfolding in the “autonomous state” of Próspera, Honduras. This isn’t a ten-year-out lab promise. It’s a clinic that, right now, will sell you an experimental gene therapy for roughly US$25,000 that claims to restore strength and roll back part of your muscular aging. The fine print: no regulator on the planet has approved it. And if it goes wrong, you’re on your own.
What’s actually happening in Próspera
The company is Minicircle, operating out of the GARM Clinic in Roatán and the Eterna Health Clinic in Dubai, and its product aims to raise follistatin levels —a protein that curbs the muscle loss that comes with age— (MIT Technology Review). It’s not an empty pitch: Bryan Johnson, the entrepreneur who stars in Netflix’s Don’t Die, underwent the therapy, and per the documentary’s own closing notes his muscle mass rose 7% in six months. Operating alongside Minicircle is Unlimited Bio, whose director Ivan Morgunov has openly admitted it’s “Próspera’s lax regulations” that let the company move this fast —an experiment that clears neither Honduras’s health regulator (ARSA) nor the FDA —the Food and Drug Administration, the U.S. agency that approves and publishes which drugs and therapies are safe for human use— (Reporteros de Investigación). This is, quite literally, medicine with no referee.
What nobody tells you
Próspera exists in a legal limbo that few of that clinic’s clients likely know about: Honduras’s Supreme Court ruled in 2024 that the legal framework behind the ZEDEs (Zones for Employment and Economic Development) was unconstitutional from its very inception. And yet Próspera keeps operating as usual, while fighting that ruling through international arbitration against the Honduran state under CAFTA-DR (LegalClarity). In other words: the legal authority under which these therapies are sold is, right now, under judicial dispute. If Próspera loses that arbitration, what happens to someone who already injected an unapproved therapy at a clinic operating under a framework a court called unconstitutional? Nobody explains that in the brochure. It’s also worth noting that part of these trials were financed through NFTs sold to the patients themselves —experimental science mixed with crypto speculation, over your own DNA.
The bet behind autonomous zones
I get the incentive, and it’s worth saying plainly: the FDA takes years and billions of dollars to approve a single therapy, and that real regulatory cost keeps treatments that might actually work off the market, simply because nobody wants to fund the obstacle course. Próspera is betting that regulatory competition —letting a small territory experiment under looser rules— can deliver in years what it takes the U.S. decades to achieve: today’s expensive, experimental protocols could get refined there before arriving, already validated, everywhere else. For context, Colombia only approved its first gene-therapy clinical trial in 2023, under strict INVIMA oversight (INVIMA) —light-years of caution compared to Roatán. But the side that can go very wrong is the exact same one that makes the upside possible: without ARSA, without the FDA, without INVIMA, nobody certifies the dose is safe, there’s no mandatory adverse-event reporting, and there’s no one to sue if something fails, because the authority you operated under is, literally, on trial for not legally existing.
I don’t know whether Próspera ends up as the birthplace of the next generation of regenerative medicine or the textbook example of what happens when you strip away all regulatory friction in exchange for speed. It’s probably both, for different people, in different years. What I do know, with the CRITERIO Method in hand, is that understanding the context before putting your money —or your body— into a bet like this isn’t optional: the absence of regulation isn’t the absence of risk, it’s risk with no one but you to carry it. Would you pay US$25,000 for a promise no regulator on Earth backs, knowing the authority that allows it is itself being judged illegitimate?
If you want to keep following how deregulation —financial, technological, or medical— is redefining where the world’s biggest risks get taken, the ViSFI Daily Briefing lands in your inbox every morning. Calculate your Criterio Score too, and share this with the buttons on this page if you think it’s useful to someone else.